Literature DB >> 23962910

PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor.

Ugur Hodoglugil1, Michelle W Carrillo, Joan M Hebert, Niki Karachaliou, Rafael C Rosell, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23962910      PMCID： PMC3966564          DOI： 10.1097/FPC.0b013e3283655091

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  91 in total

1.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Authors:  Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber
Journal:  Nat Genet       Date:  2005-10-30       Impact factor: 38.330

Review 2.  Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer.

Authors:  A De Luca; N Normanno
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

3.  The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.

Authors:  Shuji Ichihara; Shinichi Toyooka; Yoshiro Fujiwara; Katsuyuki Hotta; Hisayuki Shigematsu; Masaki Tokumo; Junichi Soh; Hiroaki Asano; Kouichi Ichimura; Keisuke Aoe; Motoi Aoe; Katsuyuki Kiura; Kenji Shimizu; Hiroshi Date; Nobuyoshi Shimizu
Journal:  Int J Cancer       Date:  2007-03-15       Impact factor: 7.396

4.  Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.

Authors:  G Liu; S Gurubhagavatula; W Zhou; Z Wang; B Y Yeap; K Asomaning; L Su; R Heist; T J Lynch; D C Christiani
Journal:  Pharmacogenomics J       Date:  2007-03-20       Impact factor: 3.550

5.  Chromosome 7p11.2 (EGFR) variation influences glioma risk.

Authors:  Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon
Journal:  Hum Mol Genet       Date:  2011-04-29       Impact factor: 6.150

6.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

9.  Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.

Authors:  Fei Ma; Tong Sun; Yuankai Shi; Dianke Yu; Wen Tan; Ming Yang; Chen Wu; Datong Chu; Yan Sun; Binghe Xu; Dongxin Lin
Journal:  Lung Cancer       Date:  2009-02-06       Impact factor: 5.705

10.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544
View more
  6 in total

1.  Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.

Authors:  H-B Qiu; W Zhuang; T Wu; S Xin; C-Z Lin; H-L Ruan; X Zhu; M Huang; J-L Li; X-Y Hou; Z-W Zhou; X-D Wang
Journal:  Pharmacogenomics J       Date:  2017-08-01       Impact factor: 3.550

2.  Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.

Authors:  Y Ma; S Xin; M Huang; Y Yang; C Zhu; H Zhao; Y Zhang; L Chen; Y Zhao; J Li; W Zhuang; X Zhu; L Zhang; X Wang
Journal:  Pharmacogenomics J       Date:  2016-04-19       Impact factor: 3.550

Review 3.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

Review 4.  Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation.

Authors:  Vladimir Jurišić; Jasmina Obradovic; Sonja Pavlović; Nataša Djordjevic
Journal:  Anal Cell Pathol (Amst)       Date:  2018-10-14       Impact factor: 2.916

5.  Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.

Authors:  Chun-Wei Xu; Lei Lei; Wen-Xian Wang; Li Lin; You-Cai Zhu; Hong Wang; Li-Yun Miao; Li-Ping Wang; Wu Zhuang; Mei-Yu Fang; Tang-Feng Lv; Yong Song
Journal:  Transl Oncol       Date:  2020-05-31       Impact factor: 4.243

6.  The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.

Authors:  Minggang Fang; Jianhong Ou; Lloyd Hutchinson; Michael R Green
Journal:  Mol Cell       Date:  2014-09-11       Impact factor: 17.970
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.